Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Alert Warns Of Adverse Events With Genzyme/Schering AG's Campath

This article was originally published in The Pink Sheet Daily

Executive Summary

The alert on idiopathic thrombocytopenia purpura comes nearly three months after the companies halted dosing in a multiple sclerosis trial of alemtuzumab due to ITP events.

You may also be interested in...



Genzyme’s Campath MS Safety Profile Expected From FDA By July; Phase III Set For Second Half

The firm expects to re-start a Phase II trial of alemtusumab in multiple sclerosis patients that was halted in 2005.

Genzyme’s Campath MS Safety Profile Expected From FDA By July; Phase III Set For Second Half

The firm expects to re-start a Phase II trial of alemtusumab in multiple sclerosis patients that was halted in 2005.

Campath Could Be Approved For Multiple Sclerosis By 2009, Genzyme Says

Genzyme CEO Termeer predicts the approval process will take three to four years following the halting of a Phase II trial in MS because of safety concerns.

Related Content

Topics

UsernamePublicRestriction

Register

PS061333

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel